About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 112 record(s)
Req # A-2022-000440
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-104401-490, Deputy Heads Weekly Meeting.Organization: Health Canada
October 2022
Req # A-2022-000446
Adverse Drug Reaction (ADR) for Abilify Maintena. Report number: 000990033. ADRs for Aripiprazole. Report numbers: E2B_05217270, E2B_05239579. ADRs for Aripiprazole, Rexulti. Report numbers: E2B_05226096, E2B_05237961. ADRs for Patiromer. Report numbers: E2B_05283076, E2B_05298575, E2B_05307033.Organization: Health Canada
October 2022
Req # A-2022-000458
Adverse Drug Reactions (ADRs). Report numbers: E2B_05261774, E2B_04899434, E2B_05162489, E2B_05292567, E2B_02305711, E2B_05267280.Organization: Health Canada
October 2022
Req # A-2022-000492
Adverse Drug Reactions (ADRs) for CELEXA:. Report numbers: 00960723, 00965330, E2B_04427134, 00960155, E2B_04408157, 00957965, E2B_04584037, E2B_04567049, E2B_04619268, E2B_04588474.Organization: Health Canada
October 2022
Req # A-2022-000494
Adverse Drug Reactions (ADRs) for CIPRALEX. Report numbers: E2B_04456755, 957786, 959624, 969070, 970648, 965887, 970029, 964218, E2B_04645800, E2B_04630344.Organization: Health Canada
October 2022
Req # A-2022-000510
Adverse Drug Reaction (ADR) for DEFERIPRONE. Report number: E2B_01716613.Organization: Health Canada
October 2022
Req # A-2022-000521
Adverse Drug Reactions (ADRs). Report numbers: E2B_05200172, E2B_05186398, 000992656.Organization: Health Canada
October 2022
Req # A-2022-000523
Adverse Drug Reactions (ADRs). Report numbers: 000992364, 000994498.Organization: Health Canada
October 2022
Req # A-2022-000528
Adverse Drug Reactions (ADRs). Report numbers: E2B_02211131, E2B_02912148, E2B_02963835, E2B_03227597, E2B_03355369, E2B_03369173, E2B_03520116, E2B_03438670, E2B_03452860, E2B_03502886.Organization: Health Canada
October 2022
Req # A-2022-000532
Adverse Drug Reactions (ADRs). Report numbers: Adverse Drug Reactions (ADRs): E2B_00471053, E2B_05414160.Organization: Health Canada
October 2022